Base editing marches on the clinic
By Michael Eisenstein,
Nature
| 05. 09. 2022
This year could see the first trials of therapies employing base editing that introduce precise single-nucleotide changes into patient genomes.
Two companies, Beam Therapeutics and Verve Therapeutics, are leading the charge of base editing therapies to the clinic. Last November, Beam got the green light from the US Food and Drug Administration (FDA) for its upcoming BEACON-101 trial that will use base editing to restore expression of fetal globin in bone marrow stem cells. In parallel, Verve is preparing to embark on an in vivo base editing trial to treat patients who have experienced a heart attack and have abnormally high cholesterol levels by targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, after obtaining promising results from preclinical work in rodents and non-human primates. “We’re optimistic about dosing our first patients in the second half of this year,” says Verve CEO and co-founder Sekar Kathiresan. The rapid progress of base editing programs is attracting interest from major pharmaceutical companies: in January, Beam entered a collaboration with Pfizer that could net the company up to $1.3 billion.
Beam’s rapid progress to the clinic — using technology developed just six years ago — has been built on the shoulders...
Related Articles
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...
By Daniel Hildebrand, The Humanist | 10.01.2025
When most people hear the word eugenics, they think of dusty history textbooks and black-and-white photographs: forced sterilizations in the early 20th century, pseudoscientific charts measuring skulls, the language of “fitness” used to justify violence and exclusion. It feels like...
By Alondra Nelson, Science | 09.11.2025
In the United States, the summer of 2025 will be remembered as artificial intelligence’s (AI’s) cruel summer—a season when the unheeded risks and dangers of AI became undeniably clear. Recent months have made visible the stakes of the unchecked use...
By Margaux MacColl, The San Francisco Standard | 09.17.2025
Designer babies are coming soon to an IVF clinic near you.
Nucleus Genomics, founded by Kian Sadeghi in 2020, when he was just 20, got its start analyzing genomes to weigh a person’s risk of everything from cancer to ADHD...